Вы находитесь на странице: 1из 5

RML

No 3-2-2/A, 1st Floor,


Beside Kumar Theatre, Kachiguda,
Hyderabad, Telangana 500027
Email id : rubraltd@gmail.com
CIN : L33100TG1991PLC013266
Website: www.rubramed.com

May 25, 2016


To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 531099
Sub: Outcome of Board Meeting
Re:
Financial Results for the Quarter and year ended March 31, 2016
Dear Sir(s),
With reference to the captioned subject, please find enclosed herewith, the Financial Results of
the Company for the Quarter and Year Ended March 31, 2016 which was approved by the Board
of Directors in their meeting held today i.e. May 25, 2016
Also attach is Limited Review Report for the year ended on March 31, 2016 given by the
Statutory Auditor of the Company.
You are requested to take note of the same.
Thanking you,
Yours faithfully,
For Rubra Medicaments Limited

MayureshTawde
Director
DIN 01999743

RUBRA MEDICAMENTS LIMITED


Part I
Sr.
No

2
a
b
c
d
e
f

3
4
5
6
7

(Rupees in Lacs)
Statement of Standalone Audited Results for the Quarter and Year ended 31/03/2016
Previous year
3 months ended
Preceeding 3 Corresponding Current Year
Particulars

Income from operations


Net Sales/Income form Operations (Net of Excise Duty)
Other Operating Income
Total Income from Operations (Net)
Expenses
Cost of Materials Consumed
Purchases of Stock-in-trade
Changes in Inventories of fininshed goods, work-in-progress and
stock-in-trade
Employee Benefit Expense
Depreciation and amortisation expenses
Other Expenses (Any item exceeding 10% of the total expenses
relating to continuing operatons to be shown separately)
Total Expenses
Profit / (Loss) from operations before other income, finance
costs and exceptional items (1-2)
Other Income
Profit / (Loss) from Ordinary activities before finance costs
and exceptional items (3+4)
Finance Cost

Profit / (Loss) from Ordinary activities after finance costs but


before exceptional items (5+6)
8 Exceptional Items
9 Profit / (Loss) from Ordinary activities before tax (7+8)
10 Tax Expenses
11 Profit / (Loss) from Ordinary activities after tax (9+10)
12 Extraordinary Items (net of tax expense)
13 Net Profit / (Loss) for the period (11+12)
14 Share of Profit/(Loss) of associates
15 Minority Interest
16 Net Profit / (Loss) after taxes, minority interest and share of profit
/(loss) of associates (13+14+15)
17 Paid-up equity share capital (Face value of the Share is Rs.10/each)
18 Reserves excluding Revaluation Reserves as per balance sheet)
of previous accounting year
19.i Earnings Per Share (EPS) (before Extraordinary items) of Rs. 10/each (not to be annualized)
a) Basic
b) Diluted
19.ii Earnings Per Share (EPS) (after Extraordinary items) of Rs. 10/(not to be annualized)
a) Basic
b) Diluted

months ended

3 months
ended in
previous year

Ended

Ended

31-Mar-16

31-Dec-15

31-Mar-15

31-Mar-16

31-Mar-15

Audited

Unaudited

Unaudited

Audited

Audited

6.95
0.00
6.95

6.47
0.00
6.47

0.00
0.00
0.00

19.54
0.00
19.54

0.00
0.00
0.00

0.00
5.45
0.00

0.00
5.08
0.00

0.00
0.00
0.42

0.00
12.59
0.00

0.00
0.00
0.00

0.45
0.00
0.78

0.45
0.00
0.69

0.00
0.00
1.10

1.80
0.00
5.83

0.42
0.00
7.06

6.68
0.27

6.22
0.25

1.52
-1.52

20.22
-0.68

7.48
-7.48

0.00
0.27

0.00
0.25

0.00
-1.52

0.00
-0.68

0.00
-7.48

0.00
0.27

0.00
0.25

0.00
-1.52

0.00
-0.68

0.00
-7.48

0.00
0.27
0.00
0.27
0.00
0.27
0.00
0.00
0.27

0.00
0.25
0.00
0.25
0.00
0.25
0.00
0.00
0.25

0.00
-1.52
0.00
-1.52
0.00
-1.52
0.00
0.00
-1.52

0.00
-0.68
0.00
-0.68
0.00
-0.68
0.00
0.00
-0.68

0.00
-7.48
0.00
-7.48
0.00
-7.48
0.00
0.00
-7.48

546.83

546.83

546.83

546.83

546.83

-508.43

-507.75

0.00
0.00

0.00
0.00

-0.03
-0.03

-0.01
-0.01

-0.14
-0.14

0.00
0.00

0.00
0.00

-0.03
-0.03

-0.01
-0.01

-0.14
-0.14

Notes:
The above results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today

The Segment-wise details are not applicable to the company as company has no segments.
Date: May 25, 2016
Place: Mumbai

Managing Director

RUBRAMEDICAMENTSLIMITED
A
1

STATEMENTOFASSETSANDLIABILITIES
EQUITYANDLIABILITIES
AsonMarch31,2016
ShareholdersFunds
(a)
ShareCapital
(b) ReservesandSurplus
(c) Moneyreceivedagainstsharewarrants
SubtotalShareholders'funds

AsonMarch31,2015

54,683,000 54,683,000
(50,842,784) (50,774,820)
3,840,216

3,908,180

2 Shareapplicationmoneypendingallotment

3 Minorityinterest


746,257

746,257


746,257


746,257

4,586,473

4,654,437





3,282,070
168,819
3,450,889





3,054,070
168,819
3,222,889



177,269
958,315



177,269
1,254,279


1,431,548
4,654,437

4 Noncurrentliabilities
(a)
Longtermborrowings
(b) Deferredtaxliabilities(net)
(c) Otherlongtermliabilities
(d) Longtermprovisions
SubtotalNoncurrentliabilities
5 Currentliabilities
(a)
Shorttermborrowings
(b) Tradepayables
(c) Othercurrentliabilities
(d) Shorttermprovisions
SubtotalCurrentliabilities
TOTALEQUITYANDLIABILITIES
ASSETS
B
1 Noncurrentassets
(a)
Fixedassets
(b) Goodwillonconsolidation
(c)
Noncurrentinvestments
(d) Deferredtaxassets(net)
(e) Longtermloansandadvances
(f)
Othernoncurrentassets
SubtotalNoncurrentassets
2 CurrentAssets
(a)
Currentinvestments
(b) Inventories
(c)
Tradereceivables
(d) Cashandcashequivalents
(e) Shorttermloansandadvances
(f)
Othercurrentassets
SubtotalCurrentassets
TOTALASSETS

1,135,584
4,586,473